Cohance Lifesciences · NSE: COHANCE · BSE: 543064
Q3 FY24 results · Oct–Dec 2023
Cohance Lifesciences reported revenue from operations of ₹219.82 crore (down 37.9% from Q3 FY23) and net profit of ₹46.75 crore (down 56.6% from Q3 FY23) for Q3 FY24 (Oct–Dec 2023), on a consolidated basis.
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 219.82 | 353.77 | −37.9% | 231.05 | −4.9% |
| Other income | 14.34 | 13.01 | +10.2% | 19.84 | −27.7% |
| Total income | 234.16 | 366.78 | −36.2% | 250.90 | −6.7% |
| Profit before tax | 65.47 | 146.08 | −55.2% | 105.41 | −37.9% |
| Net profit for the period | 46.75 | 107.72 | −56.6% | 79.56 | −41.2% |
| EPS, basic (₹) | 1.84 | 4.23 | −56.5% | 3.13 | −41.2% |
| Net margin (%) | 21.3 | 30.4 | 34.4 |
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 212.83 | 348.49 | −38.9% | 224.62 | −5.3% |
| Other income | 13.97 | 12.51 | +11.7% | 14.20 | −1.6% |
| Total income | 226.79 | 361.00 | −37.2% | 238.82 | −5.0% |
| Profit before tax | 69.50 | 147.28 | −52.8% | 100.57 | −30.9% |
| Net profit for the period | 52.36 | 109.47 | −52.2% | 74.73 | −29.9% |
| EPS, basic (₹) | 2.06 | 4.30 | −52.1% | 2.94 | −29.9% |
| Net margin (%) | 24.6 | 31.4 | 33.3 |
Consolidated
- Filed with BSE
- 06 Feb 2024, 17:31 IST
- Board meeting
- 05 Feb 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 06 Feb 2024, 17:31 IST
- Board meeting
- 05 Feb 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE